We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche’s MabThera Recommended by NICE When TNF Inhibitors Fail
Roche’s MabThera Recommended by NICE When TNF Inhibitors Fail
March 16, 2010
The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended Roche’s MabThera plus methotrexate for rheumatoid arthritis
when treatment with at least one tumor necrosis factor (TNF) inhibitor has failed.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor